NEW YORK, Jan 20 (Reuters) - Schering-Plough Corp SGP.N said on Tuesday that U.S. prescriptions for the cholesterol drugs it sells with Merck & Co (MRK.N) rose 8.7 percent in December, reclaiming most of the ground lost in November.
The U.S. drugmaker, in a regulatory filing, said combined prescriptions for Vytorin and Zetia climbed back over the 2 million mark in December to about 2.15 million from 1.98 million in November.
Citing data collected by IMS Health Inc RX.N, which follows prescription drug sales and trends for the industry, Schering-Plough said Vytorin prescriptions rose to 1.17 million from 1.08 million in November, while Zetia prescriptions climbed to 979,000 from 893,000.
Both November and December contained holidays, which can affect sales and prescriptions. (Reporting by Bill Berkrot, editing by Leslie Gevirtz)